[go: up one dir, main page]

ES2155802B1 - PROCEDURE FOR REINFORCING AND EVALUATING THE EFFECTIVENESS OF THE ANTITUMOR ACTIOVITY OF PHARMACOS IN GROSS. - Google Patents

PROCEDURE FOR REINFORCING AND EVALUATING THE EFFECTIVENESS OF THE ANTITUMOR ACTIOVITY OF PHARMACOS IN GROSS.

Info

Publication number
ES2155802B1
ES2155802B1 ES009902062A ES9902062A ES2155802B1 ES 2155802 B1 ES2155802 B1 ES 2155802B1 ES 009902062 A ES009902062 A ES 009902062A ES 9902062 A ES9902062 A ES 9902062A ES 2155802 B1 ES2155802 B1 ES 2155802B1
Authority
ES
Spain
Prior art keywords
procedure
antitumor
reinforcing
actiovity
pharmacos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES009902062A
Other languages
Spanish (es)
Other versions
ES2155802A1 (en
Inventor
Kozo Niwa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of ES2155802A1 publication Critical patent/ES2155802A1/en
Application granted granted Critical
Publication of ES2155802B1 publication Critical patent/ES2155802B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención se refiere a un procedimiento para reforzar una actividad antitumoral mediante la tostadura de una seta que contiene {be}-glucano por rayos infrarrojos lejanos, después la fermentación mediante la adición de "koji", y además la obtención de un agente aceitoso, una composición que contiene un fármaco en bruto al que se aplica tal procedimiento, un procedimiento para evaluar y esperar que la actividad antitumoral en el momento de la administración interna sea mayor cuando aumenta la relación de la cantidad formada por peróxido de lípido, y un procedimiento para evaluar la eficacia antitumoral del tratamiento aplicado al fármaco en bruto mediante el uso de los procedimientos.This invention relates to a method for reinforcing an antitumor activity by roasting a mushroom containing {be} -glucan by far infrared rays, then fermentation by adding "koji", and also obtaining an oily agent, a composition containing a crude drug to which such a procedure is applied, a procedure to evaluate and expect the antitumor activity at the time of internal administration to be greater when the ratio of the amount formed by lipid peroxide increases, and a process to evaluate the antitumor efficacy of the treatment applied to the crude drug through the use of the procedures.

ES009902062A 1998-09-17 1999-09-16 PROCEDURE FOR REINFORCING AND EVALUATING THE EFFECTIVENESS OF THE ANTITUMOR ACTIOVITY OF PHARMACOS IN GROSS. Expired - Lifetime ES2155802B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26375398 1998-09-17
JP10323374A JP2000159682A (en) 1998-09-17 1998-11-13 Method of strengthening antitumor activity of crude drug, composition containing crude drug for strengthening antitumor activity, method of evaluating antitumor effectivity treated by crude drug and method of evaluating antitumor effectivity of crud drug

Publications (2)

Publication Number Publication Date
ES2155802A1 ES2155802A1 (en) 2001-05-16
ES2155802B1 true ES2155802B1 (en) 2001-12-01

Family

ID=26546176

Family Applications (1)

Application Number Title Priority Date Filing Date
ES009902062A Expired - Lifetime ES2155802B1 (en) 1998-09-17 1999-09-16 PROCEDURE FOR REINFORCING AND EVALUATING THE EFFECTIVENESS OF THE ANTITUMOR ACTIOVITY OF PHARMACOS IN GROSS.

Country Status (19)

Country Link
JP (1) JP2000159682A (en)
KR (1) KR20000023206A (en)
CN (1) CN1255376A (en)
AU (1) AU4486299A (en)
BE (1) BE1012725A5 (en)
CA (1) CA2282234A1 (en)
DE (1) DE19944695A1 (en)
DK (1) DK199901235A (en)
ES (1) ES2155802B1 (en)
FR (2) FR2783426A1 (en)
GB (2) GB9920710D0 (en)
ID (1) ID23150A (en)
IL (1) IL131722A0 (en)
IS (1) IS5183A (en)
IT (1) IT1307267B1 (en)
NL (2) NL1013049C2 (en)
NO (1) NO994463L (en)
SE (2) SE9903307L (en)
SG (1) SG76631A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE354355T1 (en) * 2001-04-27 2007-03-15 Ajinomoto Kk A DISPERSION OF HIGHLY FINE PARTICLES CONTAINING BETA-GLUCAN, A CORRESPONDING PRODUCTION PROCESS AND THE USE OF THE DISPERSION
CA2445713A1 (en) * 2001-05-07 2002-11-14 Gab-Gyun Shin A method for preparing lactic acid fermented solution of mushroom and lactic acid fermented solution of mushroom produced thereby
JP4499979B2 (en) * 2001-05-21 2010-07-14 コンビ株式会社 Composition for controlling pathogen infection
WO2002098440A1 (en) * 2001-06-01 2002-12-12 Ajinomoto Co., Inc. Drugs for diabetes
JP4681801B2 (en) * 2002-05-15 2011-05-11 ビーエイチエヌ株式会社 Angiogenesis inhibitor and method for producing the same
US7977379B2 (en) 2002-05-15 2011-07-12 Bhn Co., Ltd. Method for angiogenesis inhibition or immunostimulation
JP4826696B2 (en) * 2003-04-07 2011-11-30 ビーエイチエヌ株式会社 Angiogenesis inhibitors
JP2005089417A (en) * 2003-09-19 2005-04-07 Noevir Co Ltd Composition for prevention/treatment of diabetes
JP4587441B2 (en) * 2004-02-12 2010-11-24 株式会社クレハ Novel diabetes treatment and food
US8034386B2 (en) 2004-09-17 2011-10-11 Ssi Co., Ltd. Extract from Agaricus blazei Murill capable of suppressing breast cancer
JP2006273835A (en) * 2005-03-04 2006-10-12 Michishi Tani Therapeutic agent for malignant tumor and food or beverage containing the same
US20120128856A1 (en) * 2009-07-31 2012-05-24 Ming East-West, Llc Maitake mushroom coffee
WO2011081024A1 (en) * 2009-12-29 2011-07-07 株式会社富士見養蜂園 Umami food, and method for producing same
CN106309511A (en) * 2016-08-30 2017-01-11 青海民族大学 Effective part of agaricus gennadii for inhibiting CDC25 enzyme as well as preparation method and application of effective part
CN106333969A (en) * 2016-08-30 2017-01-18 青海民族大学 Agaricus gennadii HDAC1 enzyme inhibition effective part and preparation method and application
WO2019104579A1 (en) * 2017-11-30 2019-06-06 SHIEH, Darbin Method for predicting and modulating susceptibility of cancer cell to programmed cell death
KR102646421B1 (en) * 2020-12-16 2024-03-12 대한민국 Method for increasing the content of physiologically active ingredients and nutrients in Grifola frondosa
KR102602787B1 (en) * 2020-12-16 2023-11-17 대한민국 Method for increasing the content of physiologically active ingredients and nutrients in Sparassis crispa
KR102584680B1 (en) * 2020-12-17 2023-10-06 대한민국 Method for manufacturing tea of Lentinula edodes tea improved physiological activities and nutrition components

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276413A (en) * 1975-12-18 1977-06-27 Kureha Chem Ind Co Ltd Production of oncostatic substances
US4177108A (en) * 1977-03-02 1979-12-04 Tetsuro Ikekawa Process for producing emitanin
DE2842691A1 (en) * 1978-09-30 1980-04-10 Karl Dr Med Theurer Activation of pharmaceuticals by irradiation - using wavelengths corresp. to absorption maxima of the substance, opt. with the simultaneous application of magnetic field
JPS57206618A (en) * 1981-06-12 1982-12-18 Noda Shiyokukin Kogyo Kk Preparation of antitumor substance
JPH02203765A (en) * 1989-02-02 1990-08-13 Nippon Beet Sugar Mfg Co Ltd Food having antitumor function and production thereof
JP3357383B2 (en) * 1991-08-14 2002-12-16 昌宏 黒田 Low molecular weight plant composition
JP2955126B2 (en) * 1992-06-22 1999-10-04 笑代 丹羽 Pharmaceutical oleaginous preparation, food oleaginous preparation and production method thereof
US6015913A (en) * 1996-09-06 2000-01-18 Mars, Incorporated Method for producing fat and/or solids from cocoa beans

Also Published As

Publication number Publication date
GB9921387D0 (en) 1999-11-10
SG76631A1 (en) 2000-11-21
IL131722A0 (en) 2001-03-19
DE19944695A1 (en) 2000-03-30
IS5183A (en) 2000-03-17
JP2000159682A (en) 2000-06-13
NL1019705A1 (en) 2002-01-29
NL1019705C2 (en) 2002-03-26
ES2155802A1 (en) 2001-05-16
BE1012725A5 (en) 2001-02-06
NL1013049A1 (en) 2000-03-21
GB9920710D0 (en) 1999-11-03
NO994463L (en) 2000-03-20
NO994463D0 (en) 1999-09-15
DK199901235A (en) 2000-03-18
KR20000023206A (en) 2000-04-25
SE9903307D0 (en) 1999-09-16
IT1307267B1 (en) 2001-10-30
FR2788697A1 (en) 2000-07-28
GB2341800A (en) 2000-03-29
ITTO990784A1 (en) 2001-03-14
SE9903307L (en) 2000-03-18
NL1013049C2 (en) 2002-01-11
FR2783426A1 (en) 2000-03-24
ID23150A (en) 2000-03-23
SE0100195D0 (en) 2001-01-24
CN1255376A (en) 2000-06-07
SE0100195L (en) 2001-01-24
ITTO990784A0 (en) 1999-09-14
AU4486299A (en) 2000-03-30
CA2282234A1 (en) 2000-03-17

Similar Documents

Publication Publication Date Title
ES2155802B1 (en) PROCEDURE FOR REINFORCING AND EVALUATING THE EFFECTIVENESS OF THE ANTITUMOR ACTIOVITY OF PHARMACOS IN GROSS.
BR9913932A (en) Use of glp-1 analogs in the treatment of stroke
GR3034162T3 (en) Liposome-encapsulated taxol, its preparation and its use
MX9306239A (en) PHARMACEUTICAL COMPOSITION FORMING AN IN VIVO LECITHIN GEL FOR THE MAINTAINED RELEASE OF A BIOLOGICALLY ACTIVE COMPOUND AND PROCEDURE FOR THE PREPARATION OF THE SAME.
ES2168395T3 (en) NEW ANTITROMBOTIC FORMULATION, PROCEDURE FOR PREPARATION AND USE OF THE SAME.
TR199701584T1 (en) New pharmaceutical composition with anesthetic effect
BR9911076A (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis C
HUP0000057A2 (en) Photochemotherapeutic compositions
BR0113085A (en) Compositions including ammonia-oxidizing bacteria to increase nitric oxide production and nitric oxide precursors, and methods of using such compositions
AR023715A1 (en) PHARMACEUTICAL COMPOSITION FOR A SUBJECT WHO NEEDS AN ELEVATION OF THE CONTENT OF NAD INTRACELLULAR, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINE TO INCREASE THE PROTECTIVE CELLULAR RESPONSES TO GENOTOXIC STRESS IN THE SKIN
DE60115842D1 (en) VALVE ARRANGEMENT
TR200001891T2 (en) ASPB28- Human insulin and its use.
BR0011225A (en) Agent to treat dry eyes, its method and use
AR003589A1 (en) USE OF AN EFFECTIVE AMOUNT OF AT LEAST ONE PEPTIDE IN A COSMETIC COMPOSITION OR FOR THE PREPARATION OF A MEDICATION INTENDED TO PARATRATE INFLAMMATION, AND A COSMETIC TREATMENT PROCEDURE THROUGH A COSMETIC COMPOSITION CONTAINING SUCH PEPTIDE.
DE60036915D1 (en) USE OF HYALURONAN FOR THE PREPARATION OF A MEDICAMENT FOR INCREASING THE EFFICACY OF CYTOTOXIC DRUGS
ES2093498T3 (en) SLIMMING COMPOSITION.
FR2765483B1 (en) MEDICINE FOR TREATING ERECTILE DYSFUNCTIONS
ATE237331T1 (en) DEUTERATED ACTIVE INGREDIENTS IN TRANSDERMAL APPLICATION
AR022250A1 (en) PHARMACEUTICAL CONTAINER OF USE FOR THE TREATMENT AND PREVENTION OF INFECTIONS BY THE VIRUS OF HEPATITIS B, PROCEDURE FOR THE TREATMENT OF PATIENTS OR PATIENTS SUSCEPTIBLE IN SUFFERING INFECTIONS BY THE VIRUS OF HEPATITIS B.
AR019327A1 (en) COMBINATION OF FENTOLAMINE AND APOMORPHINE FOR THE TREATMENT OF HUMAN SEXUAL FUNCTION AND DYSFUNCTION
BRPI0409387B8 (en) thorium-227 soft tissue bleaching complex and a complexing agent, use thereof, pharmaceutical composition, method for forming a complex, and kit for use in a method for treating soft tissue disease in a mammalian subject
CY1106702T1 (en) USE OF A COMBINATION OF A PURINE AND A NITROGEN MONOXIDE DONATOR FOR THE PREVENTION OR TREATMENT OF BENEFITS OF BENEFITS
AR013498A1 (en) USE OF IFN-ALPHA AND AMANTADINE FOR THE TREATMENT OF CHRONIC HEPATITIS C USE OF IFN-ALPHA
PT1313500E (en) DALFOPRISTINE / QUINUPRISTINE ASSOCIATES WITH CEFPIROME
AR013424A1 (en) USE OF URIDINE FOR THE PREPARATION OF A USEFUL PHARMACEUTICAL COMPOSITION TO INHIBIT THE TOXICITY OF PIRIMIDINE ANALOGS

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20010516

Kind code of ref document: A1

Effective date: 20010516